Drug intelligence / Profile preview

fadrozole + tamoxifen

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of fadrozole, a second-generation nonsteroidal aromatase inhibitor, and tamoxifen, a selective estrogen receptor modulator. This combination targets breast cancer through complementary mechanisms - fadrozole reduces estrogen production by inhibiting aromatase enzyme, while tamoxifen blocks the action of any remaining estrogen at the receptor level. The combination has shown promising results in postmenopausal women with recurrent breast cancer, with a response rate of 60% in clinical studies.

Targets

ESR1 (ERα)CYP19A1 (Aromatase)ESR2 (ERβ)CYP11B2 (Cytochrome P450 11B2)

Beyond the preview

Go deeper on fadrozole + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fadrozole + tamoxifen.

Explore the full profile